An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19.

Published in: International journal of clinical pharmacy (2022)

Our retrospective observational analysis suggested that the proportion of CVAE associated with HCQ, especially TdP and QT prolongation, was higher in patients with COVID-19. Understanding the effects of COVID-19 on the cardiovascular system is essential to providing comprehensive medical care to patients receiving HCQ treatment.

Keyphrases

coronavirus disease
cross sectional
sars cov
drug induced
respiratory syndrome coronavirus
combination therapy
replacement therapy